20-F: Waldencast PLC Files 20-F Annual Report, Details Financial Performance and Strategic Risks

Waldencast PLC's 20-F filing reveals its financial results for the year ended December 31, 2024, along with a comprehensive overview of the company's operations, risk factors, and corporate governance.

Summary

• Waldencast PLC, a global beauty and wellness company, filed its 20-F annual report for the fiscal year ended December 31, 2024.
• The report details the company's financial performance, including net revenue of $273.9 million, a 25.5% increase from the previous year.
• The company's growth strategy focuses on expanding its Obagi Skincare and Milk Makeup businesses through innovation, marketing, and geographic expansion.
• Waldencast faces risks related to internal controls, financial reporting, cash flow, liquidity, international business operations, and competition in the cosmetics industry.
• The company is subject to an ongoing SEC investigation related to the restatement of its financial results and material weaknesses in internal control.
• Waldencast relies on third-party partners for manufacturing, distribution, and e-commerce, making it vulnerable to disruptions.
• The report includes cautionary statements regarding forward-looking information and uncertainties that could affect future results.
• The company has drawn down a total of $15.0 million from the initially available $30.0 million revolving credit facility under the 2025 Credit Agreement, which as of the date of this Report, has an available balance of $15.0 million.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there is revenue growth, there are also significant risks and challenges, including an SEC investigation and material weaknesses in internal control. The sentiment is neutral as the positives and negatives balance each other out.

Positives

• Net revenue increased by 25.5% to $273.9 million.
• The company is taking steps to remediate material weaknesses in internal control.
• The company has access to a $30.0 million revolving credit facility.
• The company is expanding its distribution channels, including Ulta Beauty.

Negatives

• The company is subject to an ongoing SEC investigation.
• Material weaknesses exist in internal control over financial reporting.
• The company recorded a $5.0 million non-cash impairment charge related to goodwill.
• The company is dependent on a limited number of retailers for a significant portion of net sales.
• The company has a history of net losses and potential future declines in sales and operating results.

Risks

• The impact of the material weaknesses in internal control over financial reporting, including associated investigations, our efforts to remediate such material weakness and the timing of remediation and resolution of associated investigations.
• Our ability to achieve the anticipated benefits from any acquired business, including the Obagi and Milk acquisitions.
• Our ability to successfully implement our managements plans and strategies.
• The overall economic and market conditions, sales forecasts and other information about our possible or assumed future results of operations or our performance.
• The general impact of geopolitical events, including the impact of current wars, conflicts and other hostilities.
• The impact of any legal proceedings or investigations, including the outcome of any litigation or investigation related to or arising out of the restatement of our financial results or material weakness in internal control over financial reporting.
• The impact of adverse economic conditions in the United States or other key markets, which could negatively affect our business, financial condition, and results of operations.
• Our ability to manage expenses, our liquidity and our investments in working capital.
• Any failure to obtain governmental and regulatory approvals related to our business and products.
• Risks related to our Class A ordinary shares and warrants, including continued price volatility.
• The impact of any international trade or foreign exchange restrictions, the imposition of new or increased tariffs, foreign currency exchange fluctuations.
• The impact of any disruptions in our operations, including supply chain interruptions, as a result of trade disputes, inflation or increases in interest rates.
• Our ability to raise additional capital or complete desired acquisitions.
• Our ability to comply with financial covenants imposed by the 2025 Credit Agreement and the impact of debt service obligations and restrictive debt covenants.
• The impact of any unfavorable publicity on our business or products.
• Our ability to implement our strategic initiatives and continue to innovate Obagis and Milks existing products and anticipate and respond to market trends and changes in consumer preferences.
• Our dependence on a limited number of retailers for a significant portion of our net sales, with the loss of or challenges faced by these retailers potentially adversely affecting our results of operations.
• Changes in future exchange or interest rates or credit ratings, changes in tax laws, regulations, rates and policies.
• Our ability to retain the listing of our securities on Nasdaq and our ability to meet Nasdaqs continued listing standards, including the Periodic Filing Rule (as defined in Item 3. Key InformationD. Risk Factors) during the one-year panel monitor period.
• Other risks and uncertainties described from time to time in our filings with the SEC.

Future Outlook

The future growth, profitability, and cash flows of our Obagi Skincare and Milk Makeup businesses depend upon our ability to successfully implement our growth strategy.

Management Comments

• Our ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands.
• Our vision is fundamentally underpinned by our brand-led business model that ensures proximity to our customers, business agility and market responsiveness, while maintaining each brands distinct DNA.

Industry Context

The cosmetics industry is highly competitive, with numerous multinational companies and independent brands vying for market share across a wide range of distribution channels.

Comparison to Industry Standards

• The report mentions competitors such as Unilever, Coty, e.l.f. Beauty, LOral, LVMH, The Este Lauder Companies, P&G, Revlon, and Shiseido.
• It also notes competition from privately held brands like ONE/SIZE, Merit Beauty, Pat McGrath Labs, Ilia, Kosas, Rare Beauty, Anastasia Beverly Hills, Huda Beauty, Forma, Saie, Tarte, and Tower 28.
• The document highlights that Milk Makeup competes against other cosmetics brands on price, quality of products and packaging, perceived value, innovation, in-store presence and visibility, and e-commerce and mobile commerce initiatives.

Management Changes

Legal Proceedings

• As previously disclosed, we proactively and voluntarily self-reported our review of the historical accounting used by Obagi to the SEC.
• In connection with this matter, we received a document subpoena in September 2023.
• Although we are fully cooperating with the SECs investigation and continue to respond to requests related to this matter, we cannot predict when such matters will be completed or the outcome or potential impact of this matter on our business, investor confidence or the price of our securities.

Related Party Transactions

• In Japan, we built an alternative model to build a presence and brand awareness for our products.
• We entered into a Trademark and Know-How License Agreement with Rohto to market and sell products in Japan using the Obagi brand name.
• Under our current agreement, Rohto is licensed to manufacture and sell a series of OTC and cosmetic products developed by it under the Obagi brand name in the Japanese drug store channel, for which it pays us a license fee.
• In 2008, we expanded that relationship to provide for collaboration on the development of new products and to pursue the higher end department store channel in Japan.
• Concurrently with the Business Combination, on the Closing Date we entered into an Intellectual Property License Agreement (the IP License Agreement ) and Global Supply Services Agreement (the Supply Agreement ) with Obagi Hong Kong Limited, a subsidiary of Cedarwalk Skincare Ltd. ( Cedarwalk ) for the sale of Obagi Medical products throughout the China Region.
• Under these agreements, we will supply, or cause to be supplied through certain CMOs (as defined in the Supply Agreement), Obagi Medical products to Obagi Hong Kong and its affiliates, and Obagi Hong Kong will purchase such products, with the exclusive right to distribute and sell such products in the China Region.
• In return, Obagi Hong Kong will pay us a royalty of five and a half percent (5.5%) of gross sales of licensed products, subject to certain deductions.

Stakeholder Impact

• The report details potential impacts on shareholders, employees, customers, suppliers, and creditors.
• Shareholders face risks related to stock dilution, market fluctuations, and non-compliance with SEC and Nasdaq requirements.
• Employees may be affected by changes in compensation, benefits, and job security.
• Customers could experience disruptions in product availability, quality issues, or reputational harm.
• Suppliers may face financial or operational challenges due to economic uncertainties.
• Creditors are subject to risks related to the company's ability to comply with debt covenants and service obligations.

Next Steps

• We will continue to improve the operating effectiveness of our internal controls over financial reporting and the timeliness of those procedures during the calendar year-ended December 31, 2025.

Key Dates

Keywords

Waldencast, financial results, risk factors, internal controls, SEC investigation, Obagi, Milk Makeup, liquidity, international business, cosmetics industry